Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

640 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial.
Oaknin A, Gladieff L, Martínez-García J, Villacampa G, Takekuma M, De Giorgi U, Lindemann K, Woelber L, Colombo N, Duska L, Leary A, Godoy-Ortiz A, Nishio S, Angelergues A, Rubio MJ, Fariñas-Madrid L, Yamaguchi S, Lorusso D, Ray-Coquard I, Manso L, Joly F, Alarcón J, Follana P, Romero I, Lebreton C, Pérez-Fidalgo JA, Yunokawa M, Dahlstrand H, D'Hondt V, Randall LM; ENGOT-Cx10–GEICO 68-C–JGOG1084–GOG-3030 Investigators. Oaknin A, et al. Lancet. 2024 Jan 6;403(10421):31-43. doi: 10.1016/S0140-6736(23)02405-4. Epub 2023 Dec 1. Lancet. 2024. PMID: 38048793 Clinical Trial.
Bintrafusp Alfa for Recurrent or Metastatic Cervical Cancer After Platinum Failure: A Nonrandomized Controlled Trial.
Birrer M, Li G, Yunokawa M, Lee JY, Kim BG, Oppermann CP, Zhou Q, Nishio S, Okamoto A, Wu X, Mileshkin L, Oaknin A, Ray-Coquard I, Hasegawa K, Jehl G, Vugmeyster Y, Zhang S, Bajars M, Yonemori K. Birrer M, et al. JAMA Oncol. 2024 Sep 1;10(9):1204-1211. doi: 10.1001/jamaoncol.2024.2145. JAMA Oncol. 2024. PMID: 39052242 Free PMC article. Clinical Trial.
Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer.
Leman R, Muller E, Legros A, Goardon N, Chentli I, Atkinson A, Tranchant A, Castera L, Krieger S, Ricou A, Boulouard F, Joly F, Boucly R, Dumont A, Basset N, Coulet F, Chevalier LM, Rouleau E, Leitner K, González-Martin A, Gargiulo P, Lück HJ, Genestie C; PAOLA-1 investigators; Ray-Coquard I, Pujade-Lauraine E, Vaur D. Leman R, et al. Clin Cancer Res. 2023 Nov 1;29(21):4419-4429. doi: 10.1158/1078-0432.CCR-23-0898. Clin Cancer Res. 2023. PMID: 37756555 Free PMC article.
ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease†.
Colombo N, Sessa C, du Bois A, Ledermann J, McCluggage WG, McNeish I, Morice P, Pignata S, Ray-Coquard I, Vergote I, Baert T, Belaroussi I, Dashora A, Olbrecht S, Planchamp F, Querleu D; ESMO-ESGO Ovarian Cancer Consensus Conference Working Group. Colombo N, et al. Ann Oncol. 2019 May 1;30(5):672-705. doi: 10.1093/annonc/mdz062. Ann Oncol. 2019. PMID: 31046081 Free article.
Incorporating immune checkpoint inhibitors in epithelial ovarian cancer.
Bogani G, Moore KN, Ray-Coquard I, Lorusso D, Matulonis UA, Ledermann JA, González-Martín A, Kurtz JE, Pujade-Lauraine E, Scambia G, Caruso G, Raspagliesi F, Colombo N, Monk BJ. Bogani G, et al. Among authors: ray coquard i. Gynecol Oncol. 2025 Jan 6;193:30-40. doi: 10.1016/j.ygyno.2024.12.011. Online ahead of print. Gynecol Oncol. 2025. PMID: 39764856 Review.
Anti-IL-6R Ab tocilizumab to treat paraneoplastic inflammatory syndrome of solid cancers.
Blay JY, Brahmi M, Dufresne A, Swalduz A, Avrillon V, Assaad S, Decroisette C, Mastroianni B, Dupont M, Bourbotte-Salmon F, Ray-Coquard I, Meeus P, Dutour A, Castets M, Perol M, Heudel P. Blay JY, et al. Among authors: ray coquard i. ESMO Open. 2025 Jan 3;10(1):104088. doi: 10.1016/j.esmoop.2024.104088. Online ahead of print. ESMO Open. 2025. PMID: 39754984 Free article.
Predicting benefit from PARP inhibitors using deep learning on H&E-stained ovarian cancer slides.
Marmé F, Krieghoff-Henning EI, Kiehl L, Wies C, Hauke J, Hahnen E, Harter P, Schouten PC, Brodkorb T, Kayali M, Heitz F, Zamagni C, González-Martin A, Treilleux I, Kommoss S, Prieske K, Gaiser T, Fröhling S, Ray-Coquard I, Pujade-Lauraine E, Brinker TJ. Marmé F, et al. Among authors: ray coquard i. Eur J Cancer. 2024 Dec 26;216:115199. doi: 10.1016/j.ejca.2024.115199. Online ahead of print. Eur J Cancer. 2024. PMID: 39742559 Free article.
640 results